Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma

American Journal of Surgery

Volumn 188, Issue 5, 2004, Pages 532-537

  Ueno, Tomio ^a,b   Ko, Sae Hee ^a   Grubbs, Elizabeth ^a   Pruitt, Scott K ^a   Friedman, Henry S ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Isolated limb infusion; Isolated limb perfusion; Melanoma; Melphalan; Regional chemotherapy; Temozolomide

Indexed keywords

DIMETHYL SULFOXIDE; MELPHALAN; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR REGRESSION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACARBAZINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTREMITIES; FEMALE; INFUSIONS, PARENTERAL; MELANOMA; MELPHALAN; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, NUDE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 8544245666     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2004.07.014     Document Type: Article

References (32)

1. F.K. Storm, D.L. Morton Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity Am J Surg 150 1985 32 35
2. D.R. Minor, R.E. Allen, D. Alberts A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma Cancer 55 1985 2638 2644
3. B.B. Kroon, A.N. Van Geel, C. Benckhuijsen, J. Wieberdink Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs Anticancer Res 7 1987 441 442
4. F. Di Filippo, A. Calabro, D. Giannarelli Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion Cancer 63 1989 2551 2561
5. A.I. Skene, A.S. Bulman, T.R. Williams Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb Br J Surg 77 1990 765 767
6. J.M. Klaase, B.B. Kroon, A.N. van Geel Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan Surgery 115 1994 39 45
7. B.C. Vrouenraets, O.E. Nieweg, B.B. Kroon Thirty-five years of isolated limb perfusion for melanoma: indications and results Br J Surg 83 1996 1319 1328
8. J.F. Thompson, J.A. Hunt, K.F. Shannon, P.C. Kam Frequency and duration of remission after isolated limb perfusion for melanoma Arch Surg 132 1997 903 907
9. Aloia T, Grubbs E, Onaitis M, et al. The ability to achieve a complete response post hyperthermic isolated limb perfusion is the strongest predictor of survival. Proc Soc Surg Oncol 2001.
10. N.M. Bleehen, E.S. Newlands, S.M. Lee Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 1995 910 913
11. S.S. Agarwala, J.M. Kirkwood Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma Oncologist 5 2000 144 151
12. M.R. Middleton, J.J. Grob, N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 2000 158 166
13. G. Biasco, M.A. Pantaleo, S. Casadei Treatment of brain metastases of malignant melanoma with temozolomide N Engl J Med 345 2001 621 622
14. M.J. Paul, Y. Summers, A.H. Calvert Effect of temozolomide on central nervous system relapse in patients with advanced melanoma Melanoma Res 12 2002 175 178
15. H.S. Friedman, M.E. Dolan, A. Pegg Activity of temozolomide in the treatment of central nervous system tumor xenografts Cancer Res 55 1995 2853 2857
16. J. Wieberdink, C. Benckhuysen, R.P. Braat Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol 18 1982 905 910
17. S.R. Wedge, J.K. Porteous, E.S. Newlands Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model Cancer Chemother Pharmacol 40 1997 266 272
18. H.S. Friedman, S. Keir, A.E. Pegg O6-benzylguanine-mediated enhancement of chemotherapy Mol Cancer Ther 1 2002 943 948
19. Grubbs E, Abdel-Wahab OI, Cheng T-Y, et al. Chemotherapy resistance modulation: a novel application in regional therapy. Surgery 2004;136:210-8.
20. J.F. Thompson, P.C. Kam, R.C. Waugh, C.R. Harman Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion Semin Surg Oncol 14 1998 238 247
21. R. Mian, M.A. Henderson, D. Speakman Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion Can J Surg 44 2001 189 192
22. E.T. Krementz, R.F. Ryan Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience Ann Surg 175 1972 900 917
23. J.F. Thompson, M.P. Gianoutsos Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs World J Surg 16 1992 227 233
24. O. Eton, M. East, S.S. Legha Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases Melanoma Res 9 1999 483 489
25. K. Aigner, P. Hild, H. Breithaupt Isolated extremity perfusion with DTIC An experimental and clinical study Anticancer Res 3 1983 87 93
26. S. Ariyan, M.S. Mitchell, J.M. Kirkwood Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide Surg Gynecol Obstet 158 1984 238 242
27. M.J. Edwards, A.W. Jr Boddie, F.C. Ames, C.M. McBride Isolated limb perfusion for stage I melanoma of the extremity: a comparison of melphalan and dacarbazine (DTIC) South Med J 82 1989 985 987
28. H.A. Briele, M. Djuric, D.T. Jung Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities Cancer Res 45 1985 1885 1889
29. P. Lindner, A. Doubrovsky, P.C. Kam, J.F. Thompson Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol 9 2002 127 136
30. T.G. Zogakis, D.L. Bartlett, S.K. Libutti Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma Ann Surg Oncol 8 2001 771 778
31. E.M. Noorda, B.C. Vrouenraets, O.E. Nieweg Prognostic factors for survival after isolated limb perfusion for malignant melanoma Eur J Surg Oncol 29 2003 916 921
32. K.R. Horspool, M.F. Stevens, C.G. Newton Antitumor imidazotetrazines. 20 Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents J Med Chem 33 1990 1393 1399